newsfilter
← Latest News
Business Wire·

OS Therapies Accepted Into Johnson & Johnson Innovation - JLABS

Focus of work at JLABS on tunable Antibody Drug Conjugate linker-based platform OS Therapies (NYSE:OSTX) ("OS Therapies" or "the Company"), an ADC and Immunotherapy research and clinical-stage biopharmaceutical